Search in:

Advanced search

Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 6

Submit an article Journal homepage

529

Views

CrossRef citations to date

Altmetric

Review

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes

Nasser Mikhail Endocrinology Division, Department of Medicine, Olive-View-UCLA Medical Center, 14445 Olive View Drive, Sylmar, CA 91342, USA +1 818 364 3205; +1 818 364 4573; [email protected]

, MD MSc

Pages 845-853 | Published online: 21 May 2008

Cite this article
https://doi.org/10.1517/13543784.17.6.845

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
PubMed Web of Science ®Google Scholar
Ebert R, Unger H, Creutzfeldt W. Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from gut extracts by immunoadsorption. Diabetologia 1983;24:449-54
PubMed Web of Science ®Google Scholar
Schirra J, Nicolaus M, Roggel R, et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006;55:243-51
PubMed Web of Science ®Google Scholar
Kreymann, Ghatei MA, Williams G, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-4
PubMed Web of Science ®Google Scholar
Elahi D, McAloon-Dyke M, Fukagawa NK, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994;51:63-74
PubMed Web of Science ®Google Scholar
Schirra J, Sturm K, Leicht P, et al. Exendin (9-39) amide is an antagonist of glucagon-like peptide-1 (7-36) amide in humans. J Clin Invest 1998;101:1421-30
PubMed Web of Science ®Google Scholar
Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of GLP-1 (7-36 amide) but not of synthetic human GIP in patients with type 2 diabetes mellitus. J Clin Invest 1993;91:301-7
PubMed Web of Science ®Google Scholar
Meier JJ, Goetze O, Anstipp J, et al. Gastric inhibitory polypeptide (GIP) does not inhibit gastric emptying in man. Am J Physiol 2003;286:E621-5
Web of Science ®Google Scholar
Habener JF. The incretin notion and its relevance to diabetes. Endocrinol Metab Clin North Am 1993;22:775-95
PubMed Web of Science ®Google Scholar
Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316-22
PubMed Web of Science ®Google Scholar
Nathan DM, Schreiber E, Fogel H, et al. Insulinotropic action of glucagon-like peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 1992;15:270-6
PubMed Web of Science ®Google Scholar
Krarup T, Saubrey N, Moody AJ, et al. Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus. Metabolism 1987;36:677-82
PubMed Web of Science ®Google Scholar
Vilsboll T, Krarup T, Deacon C, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetes. Diabetes 2001;50:609-13
PubMed Web of Science ®Google Scholar
Toft-Nielsen M, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-23
PubMed Web of Science ®Google Scholar
Lugari R, Dei Cas A, Ugolotti D, et al. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non-insulin dependent) diabetes. Horm Metab Res 2002;34:150-4
PubMed Web of Science ®Google Scholar
Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88:220-4
PubMed Web of Science ®Google Scholar
DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
PubMed Web of Science ®Google Scholar
Buse JB, Henry RR, Han J, et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
PubMed Web of Science ®Google Scholar
Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
PubMed Web of Science ®Google Scholar
Zinman B, Hoogwerf BJ, Garcia SD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007;146:477-85
PubMed Web of Science ®Google Scholar
Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93
PubMed Web of Science ®Google Scholar
American Diabetes Association. Standards of medical care in diabetes, 2007. Diabetes Care 2007;30(Suppl 1):S4-41
PubMedGoogle Scholar
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. Systemic review and meta-analysis. JAMA 2007;298:194-206
PubMed Web of Science ®Google Scholar
Heine RJ, Van Gaal LF, Johns D, et al.; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. A randomized trial. Ann Intern Med 2005;143:559-69
PubMed Web of Science ®Google Scholar
Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority trial. Diabetologia 2007;50:259-67
PubMed Web of Science ®Google Scholar
Davis SN, Johns D, Maggs D, et al. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007;30:2767-72
PubMed Web of Science ®Google Scholar
Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-47
PubMed Web of Science ®Google Scholar
Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004;53:2397-403
PubMed Web of Science ®Google Scholar
Gutniak MK, Junitti-Berggren L, Hellstrom P, et al. Glucagon-like peptide 1 enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 1996;19:857-63
PubMed Web of Science ®Google Scholar
Ahmad SR, Swann J. Exenatide and rare adverse events [letter]. N Engl J Med 2008;358:1970-2
PubMed Web of Science ®Google Scholar
Harder H, Mscodont LN, Thi TDT, Drmedski AA. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004;27:1915-21
PubMed Web of Science ®Google Scholar
Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care 2004;27:1335-42
PubMed Web of Science ®Google Scholar
Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7
PubMed Web of Science ®Google Scholar
Raz I, Hanefeld M, Xu L, et al. for the Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71
PubMed Web of Science ®Google Scholar
Pratley RE, Kamel-Jauffret S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38:423-8
PubMed Web of Science ®Google Scholar
Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132-8
PubMed Web of Science ®Google Scholar
Charbonnel B, Karasik A, Liu J, et al.; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43
PubMed Web of Science ®Google Scholar
Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5
PubMed Web of Science ®Google Scholar
Goldstein BJ, Feinglos MN, Lunceford JK, et al.; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87
PubMed Web of Science ®Google Scholar
Mannuci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489-94
PubMed Web of Science ®Google Scholar
Green BD, Irwin N, Duffy NA, et al. Inhibition of dipeptidyl peptidase-IV activity by meformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 2006;547:192-9
PubMed Web of Science ®Google Scholar
Hermansen K, Kipnes M, Luo E, et al.; Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes inadequately controlled on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45
PubMed Web of Science ®Google Scholar
Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008; Feb 18 [Epub ahead of print]
Google Scholar
Rosenstock J, Brazg R, Andryuk PJ, et al.; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-68
PubMed Web of Science ®Google Scholar
Garber AJ, Schweizer A, Baron A, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166-74
PubMed Web of Science ®Google Scholar
Rosenstock J, Baron MA, Camisasca RP, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175-85
PubMed Web of Science ®Google Scholar
Fonesca V, Dejager S, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-55
PubMed Web of Science ®Google Scholar
Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007;24:955-61
PubMed Web of Science ®Google Scholar
Nauck MA, Meininger G, Sheng D, et al.; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205
PubMed Web of Science ®Google Scholar
Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. Diabetes Care 2007;30:217-23
PubMed Web of Science ®Google Scholar
Bolli G, Dotta F, Rochette E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82-90
PubMed Web of Science ®Google Scholar
Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008;25:435-41
PubMed Web of Science ®Google Scholar
Januvia (sitagliptin phosphate). Product insert. Merk & Co., Station, NJ, USA; 2007
Google Scholar
Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved tolerance in diabetic rats. Diabetes 1999;48:2270-6
PubMed Web of Science ®Google Scholar
Mu J, Woods J, Zhou Y, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006;55:1695-704
PubMed Web of Science ®Google Scholar
Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454-70
PubMed Web of Science ®Google Scholar
Nathan DM, Buse JB, Davidson M, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29:1963-72
PubMed Web of Science ®Google Scholar
Bolen S, FeldmanL, Vassy J, et al. Systemic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99
PubMed Web of Science ®Google Scholar
Mikhail N. Exenatide: a novel approach for treatment of type 2 diabetes. South Med J 2006;99:1271-9
PubMed Web of Science ®Google Scholar
Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007;64:317-27
PubMed Web of Science ®Google Scholar
Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862-4
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date